MALTA MEDICINES AUTHORITY

IN012/12 Appendix 1 Version 2

Certificate No: **MT/026HM/2026**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER[1],[2]

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC

The Malta Medicines Authority confirms the following:
The manufacturer **ASG Pharma Ltd.**
Manufacturer's alternative name **N/A**
Site address **Level 3 and Level -1 ADC Building Triq l-Esportaturi Central Business District CBD1040 Mriehel Malta.**
Additional details on units inspected **N/A**

Other: Is a manufacturer of Cannabis for Medicinal Purposes and has been inspected in accordance with Art 4 (2d) of the Production of Cannabis for Medicinal and Research Purposes Act (Chapter 578 of the Laws of Malta).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **25th – 28th August 2025**, it is considered that it complies with the principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572[3] and Commission Delegated Regulation (EU) 2017/1569 as appropriate.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (http://eudragmdp.ema.europa.eu/)

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

6th April 2026

Dr. Mark Cilia[1]
Director Inspectorate &
Enforcement Directorate
Malta Medicines Authority
Tel: 00356 234 39 119

[1] The certificate referred to in paragraph 111(5) of Directive 2001/83/EC is also applicable to importers.
[2] Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.

Part 2

☐ Human Medicinal Products*	
1 MANUFACTURING OPERATIONS – MEDICINAL PRODUCTS *	
1.2	**Non-sterile products**
	1.2.2 Batch certification
1.5	**Packaging**
	1.5.1 Primary packing 1.5.1.6 Liquids for internal use 1.5.1.17 Other: non-sterile medicinal products: cannabis dried flowers
	1.5.2 Secondary packing
1.6	**Quality Control testing**
	1.6.2 Microbiological: non-sterility
	1.6.3 Chemical/Physical

6th April 2026

Dr. Mark Cilia[1]
Director Inspectorate &
Enforcement Directorate
Malta Medicines Authority
Tel: 00356 234 39 119

2 **IMPORTATION OF MEDICINAL PRODUCTS***	
2.1	**Quality control testing of imported medicinal products**
	2.1.2 Microbiological: non-sterility
	2.1.3 Chemical/Physical
2.2	**Batch certification of imported medicinal products**
	2.2.2 Non-sterile products
2.3	**Other importation activities**
	2.3.2 Importation of intermediate which undergoes further processing

Any restrictions or clarifying remarks related to the scope of this certificate:
This certificate is limited in scope to cannabis products (cannabis dried flowers and oils) for medicinal use. Therefore medicinal products are not within the scope of this certificate.

1.2.2 is limited to batch certification of cannabis batches packaged on-site.
1.5.1 is limited to the affixing of a label on the primary packaging of the dried flowers or oils.

Importation is limited to oils and dried flowers that require the affixing of a label on the primary packaging material as certified in activity 1.5.1.

The vault for storing cannabis products is situated on Level -1 and the QC testing takes place on Level 3 of ADC Building.

6th April 2026

Dr. Mark Cilia[1]
Director Inspectorate &
Enforcement Directorate
Malta Medicines Authority
Tel: 00356 234 39 119